• UK approves 1 mg dose of ALK’s EURneffy adrenaline nasal spray for children aged 4 and up

  According ALK, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved use of a 1 mg dose of EURneffy adrenaline nasal spray for the treatment of anaphylaxis in children aged 4 and older who… [Read more . . .]

• RDD 2026 in review

  In fact, he said, “Solution-based spray drying to increase bioavailability is often the wrong approach for Class 1 iBCS APIs.” Using examples from some of the more than 300 molecules for inhalation he has worked… [Read more . . .]

• Lupin partners with ERN for launch Luforbec beclometasone / formoterol MDI in Spain

  Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… [Read more . . .]

• MannKind initiates Phase 2 INFLO-2 trial of MNKD-201 nintedanib DPI in patients with IPF

  MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… [Read more . . .]

• SoftOx Solutions initiates Phase 1 SIS-02 trial of SIS hypochlorous acid inhalation solution

  SoftOx Solutions announced the initiation of its Phase 1 SIS-02 study of SIS hypochlorous acid inhalation solution in healthy volunteers as part of a European Defense Fund-supported effort to develop the inhalation solution as a… [Read more . . .]

• Scienture announces new US patent covering Rezenopy naloxone nasal spray

• Nebu-Flow gets £2 million Scottish Enterprise grant for continued development of its nebulizer technology

• FDA approves MannKind’s sBLA for pediatric use of Afrezza insulin DPI

• Kvvit acquires rights to Merz’s Inbrija levodopa DPI in mainland China, Hong Kong, and Macao

• Inhaled SSO developer Rage Bio rebrands as Atisama Therapeutics

More news . . .